✦ LIBER ✦

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

✍ Scribed by Winnie Yeo; Philip J. Johnson

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 150 KB
Volume: 43
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21051

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lamivudine in the treatment of hepatitis

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

✍ Yeo, Winnie; Steinberg, Joyce L.; Tam, John S.; Chan, Paul K.S.; Leung, Nancy W. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

Hepatitis B virus (HBV) reactivation has been described in cancer patients who received cytotoxic/immunosuppressive therapy and may result in liver damage of varying degrees of severity. There is no known effective treatment. Lamivudine, a nucleoside analogue, has been found to suppress HBV replicat

Modeling complex decay profiles of hepat

Modeling complex decay profiles of hepatitis B virus during antiviral therapy

✍ Harel Dahari; Emi Shudo; Ruy M. Ribeiro; Alan S. Perelson 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

Typically, hepatitis B virus (HBV) decays in patients under therapy in a biphasic manner. However, more complex decay profiles of HBV DNA (e.g., flat partial response, triphasic, and stepwise), for which we have no clear understanding, have also been observed in some treated patients. We recently in

Patterns of circulating hepatitis B viru

Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy

✍ Wei Zhang; Hans Jörg Hacker; Mehmet Tokus; Thomas Bock; Claus H. Schröder 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

## Abstract We examined whether lamivudine treatment, in addition to the rapid decline of HBV serum DNA described in a large number of laboratories, causes changes in composition and amount of discernable circulating viral DNA and RNA. Nucleic acids were extracted from serial serum samples of a pat

Prevention of hepatitis B reactivation w

Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy—A prospective case series

✍ Themistoklis Vassiliadis; Vassilia Garipidou; Konstantinos Tziomalos; Vassilios 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

Biphasic clearance kinetics of hepatitis

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

✍ Dr. Manuel Tsiang; James F. Rooney; John J. Toole; Craig S. Gibbs 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

In a recent phase II clinical study, 13 chronic hepatitis B-infected patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4.1-log 10 decrease in plasma hepatitis B virus (HBV)-DNA levels. The decline of viral load during therapy displayed a biphasic kinetic profile th

Acute exacerbation and hepatitis B virus

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

✍ Yun-Fan Liaw; Rong-Nan Chien; Chau-Ting Yeh; Sun-Lung Tsai; Chia-Ming Chu 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication, but its long-term use may be associated with HBV tyrosine-methionine-aspartate-aspartate (YMDD) motif mutation. To examine the clinical features and course after emergence of YMDD mutants, 55 patients who received lamivudine th